Medicis Pharmaceutical (MRX +38%) hovers just below the $44 takeout price offered from Valeant...


Medicis Pharmaceutical (MRX +38%) hovers just below the $44 takeout price offered from Valeant Pharmaceuticals (VRX +14.8%), suggesting that investors aren't expecting any better offers to emerge. Canaccord plays down likelihood of higher bids from other competitors, primarily because the fit is a good one for both companies and supported by both boards. RBC agrees, saying it's a good strategic fit that will likely add 10% to VRX's bottom line.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs